Santen Pharmaceutical Co Ltd 2024 SR
The report highlights Santen's commitment to ophthalmology and its CORE PRINCIPLE of contributing to people's health through nature-inspired innovation. The company details its progress in R&D for pediatric myopia and ptosis, as well as its Santen Vision for the Earth 2050 environmental strategy. Notable achievements include a 36% reduction in Scope 1 and 2 emissions since fiscal 2019 and the validation of its 2030 targets by the Science Based Targets initiative (SBTi). Furthermore, the report emphasizes digital transformation initiatives, such as the global rollout of generative AI and robotic process automation to improve operational efficiency.
Company: Santen Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2024
Type: SR
Pages: 20
Santen Pharmaceutical Co Ltd
Sustainability Report
The report highlights Santen's commitment to ophthalmology and its CORE PRINCIPLE of contributing to people's health through nature-inspired innovation. The company details its progress in R&D for pediatric myopia and ptosis, as well as its Santen Vision for the Earth 2050 environmental strategy. Notable achievements include a 36% reduction in Scope 1 and 2 emissions since fiscal 2019 and the validation of its 2030 targets by the Science Based Targets initiative (SBTi). Furthermore, the report emphasizes digital transformation initiatives, such as the global rollout of generative AI and robotic process automation to improve operational efficiency.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
2023
Fiscal Year
2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women in Management
Net Zero Target